# The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

- Source: PR Newswire
- Published: 2026-10-25T10:37:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/the-results-of-phase-iii-optitrop-lung06-study-of-sacituzumab-tirumotecan-sac-tmt-presented-as-an-esmo-oral-presentation-and-simultaneously-published-in-the-new-england-journal-of-medicine-302918758.html
- Canonical: https://groundlevelnews.com/story/the-results-of-phase-iii-optitrop-lung06-study-of-sacituzumab-tirumote-2ab178/

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._